What the Supreme Court’s Roundup Ruling Means for Your Cancer Claim
If you or someone you love used Roundup and later heard the words “non-Hodgkin lymphoma,” you already know what the floor dropping feels like. And now you have heard that the United States Supreme Court just ruled in favor of the company that made the weedkiller. Your first thought is probably simple and frightening: Is my case over?
We are going to answer that question honestly. Not with false comfort, and not with surrender. The ruling is significant — there is no point pretending otherwise. But “Bayer won” does not automatically mean “you lost.” The opinion’s exact scope is still being analyzed by lawyers across the country, and what it covers, what it does not cover, and which claims survive are questions that turn on the specific theory your case was filed under, the state you live in, and how your lawyer pleads what comes next.
What we can tell you right now is this: the ruling centers on a legal doctrine called preemption — the idea that when the federal government approves a pesticide label through the Environmental Protection Agency, that federal approval may override state lawsuits claiming the label should have carried a cancer warning. If the Court held that FIFRA — the federal pesticide law — preempts those state-law failure-to-warn claims, then the single most common theory in Roundup litigation has been narrowed, possibly significantly. But failure-to-warn is not the only theory. Design defect claims, fraudulent-concealment claims, and certain state consumer-protection claims may follow different paths. Whether yours does depends on your case — and on whether your lawyer reads the opinion carefully enough to find the doors it left open.
That is what this page is for. We are Attorney911 — The Manginello Law Firm, PLLC. We handle toxic-tort and catastrophic-injury cases. We are writing this to give you, in plain language, what the ruling means, what survives, what does not, and what you should do in the days and weeks ahead. This is legal information, not legal advice — but it is the kind of legal information that comes from attorneys who have spent their careers inside this fight, and who know how the other side builds its defenses because one of us used to sit on their side of the table.
The Ruling: What Happened and Why It Matters Nationwide
The Supreme Court’s decision in the Roundup preemption case — Monsanto Company v. Durnell, No. 24-1068, argued before the Court on April 27, 2026 — resolved a question that has hung over the entire Roundup litigation for years: does the Federal Insecticide, Fungicide, and Rodenticide Act, the federal law that governs pesticide labeling, expressly preempt state-law claims that would require a cancer warning on a product whose label the EPA approved without one?
The Court ruled in Bayer’s favor. That means the preemption argument — the argument that federal law blocks certain state tort claims about what the label should have said — won. The practical effect is that the primary theory of liability in Roundup litigation, failure to warn, has been constrained at the highest judicial level, in a ruling that binds every federal and state court in the country.
A Supreme Court ruling on FIFRA preemption operates as the supreme law of the land under the Supremacy Clause, displacing any conflicting state tort law across all fifty states.
That is not a footnote. It is the structural reality. When the Supreme Court speaks on federal preemption, it does not matter whether your case is in California, Missouri, Pennsylvania, or any other state — the ruling reaches into every courthouse in the nation. The Roundup multidistrict litigation, centralized in the Northern District of California before Judge Vince Chhabria, had approximately 3,909 actions pending as of mid-2026, with thousands more filed in state courts across the country. Every one of those cases is now affected.
But here is what the ruling does not automatically do. It does not dismiss every case. It does not erase every legal theory. It does not vacate settlements already reached. And it does not answer every question about what a surviving Roundup claim looks like — because the opinion’s exact scope, its precise language, and how lower courts will interpret its boundaries are all still being analyzed. What the ruling almost certainly does is narrow the path. The question is how much, and for whom.
We need to be honest with you about that, because dishonesty in either direction — “your case is fine” or “your case is dead” — serves the person saying it, not the person hearing it. The truth is that the ruling is a significant legal development that requires a prompt, case-specific legal evaluation. Which theory your case was filed under, whether that theory survives, and what alternative pathways remain — those are the questions that determine what happens next. And they cannot be answered by a headline.
FIFRA Preemption in Plain English: Why a Federal Labeling Law Can Override Your State Claim
To understand what just happened, you need to understand the collision between two systems of law that were never designed to coexist comfortably.
Roundup is a pesticide. Pesticides in this country are governed by FIFRA — the Federal Insecticide, Fungicide, and Rodenticide Act — which requires the EPA to review and approve the labeling of every pesticide before it can be sold commercially. The EPA has historically maintained that glyphosate, the active ingredient in Roundup, is “not likely to be carcinogenic to humans.” Based on that position, the EPA approved Roundup’s label without a cancer warning.
Meanwhile, in 2015, the International Agency for Research on Cancer — IARC, the cancer-research arm of the World Health Organization — classified glyphosate as “probably carcinogenic to humans.” That classification is what generated the scientific dispute that drove the litigation. If IARC is right, Roundup may cause cancer. If the EPA is right, it does not. And the legal question the Supreme Court just answered is not which agency is correct about the science — it is whether the EPA’s federal label approval blocks state courts from even hearing claims that the label should have warned about cancer.
FIFRA’s express preemption provision — barring states from imposing labeling requirements different from or in addition to those required under the federal scheme — is the doctrinal fulcrum of the ruling.
Here is what that means in human terms. Bayer’s argument to the Supreme Court was essentially this: “The federal government, through the EPA, reviewed our label and decided it did not need a cancer warning. A state court that says we should have added one is imposing a labeling requirement different from what the federal government required. FIFRA says states cannot do that. Therefore, the state-law failure-to-warn claim is preempted — blocked — by federal law.”
The Supreme Court agreed with that argument, at least in substantial part. That means a state-law claim saying “Monsanto should have put a cancer warning on the Roundup label” may now be foreclosed by the fact that the EPA — an agency that said glyphosate is not likely to be carcinogenic — approved the label without one.
The tension here is real and it is uncomfortable. The EPA’s position on glyphosate has been contested, has shifted with different administrations, and has been criticized by scientists who point to the IARC classification and to mechanistic studies suggesting carcinogenic potential. But FIFRA preemption does not ask whether the EPA was right. It asks whether the EPA’s label approval creates a federal requirement that state law cannot add to. The Supreme Court’s ruling says, in substance, that it does.
This is not the first time preemption has reshaped mass-tort litigation. The Supreme Court has confronted similar questions in pharmaceutical cases — with brand-name drugs (where the Court allowed failure-to-warn claims to proceed in Wyeth v. Levine because the manufacturer could have unilaterally strengthened its warning) and with generic drugs (where the Court preempted failure-to-warn claims in PLIVA v. Mensing because generic manufacturers are required to copy the brand label and cannot change it). The Roundup ruling lives in the same doctrinal neighborhood, but the pesticide context has its own statutory text, its own regulatory framework, and its own history. The opinion’s specific language matters enormously, and lawyers across the country are reading every word of it right now.
Which Roundup Claims Are Affected — and Which May Survive
This is the section that matters most to you, because this is where the ruling’s impact on your specific case lives. Not every legal theory in Roundup litigation is a failure-to-warn claim. And the preemption doctrine, as a general matter, targets state labeling requirements specifically — not every theory of manufacturer liability. The question is which theories the opinion reaches and which it leaves alone.
Failure to warn — the theory most directly threatened. The dominant theory in Roundup litigation has been that Monsanto knew or should have known of glyphosate’s carcinogenic risk and failed to place an adequate cancer warning on the product label. This is the theory most directly in the preemption crosshairs, because it is the theory that most clearly seeks to impose a labeling requirement different from what the EPA approved. If the Court held that FIFRA preempts this theory — and the ruling in Bayer’s favor suggests it did, at least in substantial part — then failure-to-warn claims that depend on saying “the label should have warned about cancer” may be foreclosed in courts across the country.
But even within failure-to-warn, the exact language of the opinion matters. Does it preempt all failure-to-warn claims, or only those that directly conflict with the EPA’s specific label approval? Does it leave room for claims based on information Monsanto possessed that it never submitted to the EPA? Does it distinguish between claims about what the label said and claims about what Monsanto told doctors, agricultural workers, or the public outside the label? These are questions the opinion’s text will answer, and they are questions your lawyer must examine before concluding that your failure-to-warn claim is gone.
Design defect — the theory that may survive. A design-defect claim does not say “the label was inadequate.” It says “the product itself was unreasonably dangerous as designed — the chemical formulation was inherently hazardous, regardless of what the label warned about.” This theory operates independently of labeling requirements, and it may not be reached by a preemption ruling focused on FIFRA’s labeling provisions. The strategic pivot after this ruling, for many plaintiffs, will be toward reframing cases as design-defect claims rather than failure-to-warn claims.
The challenge with design defect is causation. Proving that Roundup’s chemical formulation was unreasonably dangerous as designed requires expert testimony on general causation — that glyphosate can cause non-Hodgkin lymphoma — and specific causation — that this plaintiff’s NHL was caused by their Roundup exposure, not by something else. The IARC classification provides a scientific foundation for general causation. Dose-response modeling, temporal relationship between exposure and diagnosis, and confounder screening (ruling out other known NHL risk factors) support specific causation. This is harder than failure-to-warn, but it is not impossible, and it is the path many surviving cases will take.
Fraudulent concealment and suppression — the theory that may survive on an independent-duty theory. Allegations that Monsanto suppressed unfavorable scientific findings, influenced regulatory assessments through ghostwriting and scientific-influence operations, and cultivated relationships with EPA officials while privately possessing evidence of carcinogenic risk — these allegations support a fraudulent-concealment theory that may survive preemption if it is grounded in an independent duty not to deceive, rather than in a duty to warn through the product label. The distinction matters: a claim that says “you lied to me about the safety of your product” is different from a claim that says “your label should have said something different.” If the opinion’s preemption holding is limited to labeling requirements, fraudulent-concealment claims based on independent duties may survive.
This theory also supports punitive damages. If a jury finds that Monsanto suppressed research, ghostwrote scientific literature, or manipulated the regulatory process, that conduct — if proven — is the kind of deliberate concealment that justifies punishment damages on top of compensation. A preemption ruling that narrows failure-to-warn claims does not necessarily eliminate the punitive exposure that flows from fraudulent concealment, because the fraud theory rests on different conduct than the labeling theory.
State consumer-protection and unfair-trade-practices statutes — the alternative avenue. Many states have consumer-protection statutes that prohibit deceptive marketing, misrepresentation, and unfair trade practices. These statutes may provide a pathway that is not directly addressed by a FIFRA preemption holding focused on labeling requirements. If Monsanto marketed Roundup as safe while internally possessing evidence of carcinogenic risk, a state consumer-protection claim based on deceptive marketing may survive even if a tort claim based on inadequate labeling does not. The viability of this theory depends on the specific state’s statute, its elements, and whether it has been used in product-liability contexts before.
Negligence in testing and research — the theory that may survive as a non-labeling claim. A claim that Monsanto failed to exercise reasonable care in studying, researching, and evaluating glyphosate’s long-term carcinogenic effects is a negligence claim that does not necessarily depend on what the label said. It depends on what the company did — or did not do — to investigate the safety of its own product before and during decades of commercial distribution. If framed as a duty of reasonable care in research and testing, independent of any labeling requirement, this theory may not be reached by a preemption ruling focused on FIFRA’s labeling provisions.
The common thread across all surviving theories is this: the further the claim gets from “the label should have said something different,” the more likely it is to survive a FIFRA preemption ruling. Claims about the product’s design, about the company’s conduct outside the label, about deception and suppression, and about state consumer-protection violations all operate in territory that the preemption doctrine may not reach. Whether your case sits in that territory is the first question a lawyer must answer after reading the opinion.
What Happens to Existing Roundup Cases and Settlements
If your case is already filed — whether in the MDL in the Northern District of California or in a state court — you are facing a landscape that has shifted under your feet. Here is what we know and what we do not know.
Settled claims. If your claim was already resolved through Bayer’s settlement framework — the company established a multi-billion-dollar settlement program covering tens of thousands of claims — the ruling likely does not reopen settled cases. Settlements are contracts. Once you have signed a release and accepted payment, the resolution is final unless there was fraud in the settlement process itself. The ruling may affect the value of future settlements and the leverage of unresolved claims, but it generally does not unwind completed ones.
Pending claims in the MDL. The MDL before Judge Chhabria in the Northern District of California had approximately 3,909 actions pending as of mid-2026. Those cases now face a changed legal landscape. If the ruling preempts failure-to-warn claims, plaintiffs whose cases were pleaded primarily on that theory may face motions to dismiss or motions for summary judgment from Monsanto. The MDL court will need to determine how the opinion applies to the pending inventory — whether it requires dismissal of all failure-to-warn claims, or whether it allows some to proceed on non-preempted theories. This process will take months, and during that time, the status of individual cases may be uncertain.
Pending claims in state court. Cases filed in state court — particularly in jurisdictions with plaintiff-friendly tort systems and strong consumer-protection statutes — may be better positioned than federal cases, depending on how the opinion interacts with state-specific legal frameworks. A state court in Missouri (where Monsanto’s historic headquarters in St. Louis has been a major litigation venue) or in Pennsylvania may interpret the opinion’s scope differently than a federal court in California. Forum selection now matters more than ever.
Bayer’s settlement posture. Before this ruling, Bayer had allocated billions across tens of thousands of claims through its settlement framework, and individual bellwether verdicts had reached significant sums. The ruling reshapes that calculus. Bayer may harden its settlement posture for claims it believes are fully preempted — offering less, or refusing to settle at all. But for claims built on non-preempted theories — design defect, fraudulent concealment, state consumer-protection violations — Bayer remains exposed, and the asymmetric leverage of a well-pleaded case may actually increase. A plaintiff whose lawyer has carefully pleaded a design-defect claim with strong causation proof may have more negotiating power, not less, because Bayer knows that the preempted claims are dropping out and the surviving claims are the ones that can actually reach a jury.
New filings. If you have not yet filed a claim but were considering doing so, the ruling does not necessarily close the door — but it changes which door you walk through. A new case filed primarily on a failure-to-warn theory may face an immediate preemption motion. A new case filed on a design-defect theory, with strong specific-causation proof and in a favorable forum, may still proceed. The decision of whether, where, and how to file has become more strategic, not less.
Can You Still File a New Roundup Lawsuit?
The short answer is: possibly, depending on the theory, the jurisdiction, and the deadline.
The longer answer requires understanding three things: what the ruling preempts, what your state’s deadline is, and what your specific evidence supports.
The theory question. As discussed above, the ruling most directly affects failure-to-warn claims. If your potential case would be built primarily on “Monsanto should have warned about cancer on the label,” the ruling may foreclose that path. But if your case can be built on “the product was unreasonably dangerous as designed,” or “Monsanto deceived the public about its safety,” or “Monsanto violated my state’s consumer-protection laws,” those theories may survive. The question is whether the evidence supports those theories — and that requires a case-specific evaluation.
The deadline question. Every state has a statute of limitations for personal injury claims — typically between two and six years, depending on the jurisdiction. For a latent disease like non-Hodgkin lymphoma, which may appear years or decades after exposure to Roundup, many states apply a “discovery rule” — the clock does not start when you were exposed to the weedkiller, but when you knew or should have known that your cancer was connected to that exposure. In practical terms, that often means the clock starts around the date of diagnosis, or when you first learned of a possible connection between Roundup and NHL.
But there is a critical caveat: some states also have a “statute of repose” — an outer deadline that can cut off a claim even before you discover the connection. Statutes of repose are different from statutes of limitations, and the discovery rule does not defeat them. If your state has a repose statute that has already run, it may not matter that you only recently connected your cancer to Roundup — the door may be closed regardless. Whether a repose statute applies to your situation, and whether it has run, is a question that depends on your state’s specific law and the dates of your exposure and diagnosis. This is not something to guess about. It is something to check, with a lawyer, now.
The evidence question. A new Roundup case — especially one built on a non-preempted theory — requires specific proof. You need to establish exposure: when, where, how often, and for how long you used Roundup. You need to establish diagnosis: the type of NHL, the stage, the treatment regimen, the prognosis. And you need to establish specific causation: that your NHL was more likely than not caused by your Roundup exposure, not by other known risk factors. Purchase records, agricultural-use logs, employment records if you used Roundup professionally, and complete medical records are the foundation. Some of these records degrade over time — retail purchase records and agricultural-use logs in particular — which is why gathering them early matters.
The bottom line on new filings: the ruling did not make it impossible to file. It made it more important to file the right case, in the right court, on the right theory, with the right evidence, before the right deadline. That is a taller order than it was before the ruling — but it is not a closed door.
The Medicine: Non-Hodgkin Lymphoma and What It Takes From a Life
Non-Hodgkin lymphoma is a cancer of the lymphatic system — the body’s network of lymph nodes, spleen, thymus, and bone marrow that is part of the immune system. It begins when white blood cells called lymphocytes develop abnormalities: they multiply uncontrollably, they do not die as normal cells do, and they collect in lymph nodes and other lymphatic tissue, causing tumors.
There are many subtypes of NHL — more than 70, depending on the type of lymphocyte involved (B-cell or T-cell), the rate of growth (indolent or aggressive), and other molecular characteristics. The most common subtype in adults is diffuse large B-cell lymphoma, an aggressive form. Other subtypes include follicular lymphoma (indolent), mantle cell lymphoma, and Burkitt lymphoma. Five-year survival rates vary dramatically by subtype and stage — from over 90 percent for some localized, low-grade forms to under 60 percent for advanced aggressive disease.
Treatment depends on the subtype, stage, and the patient’s overall health. For many patients, the regimen includes R-CHOP chemotherapy — a combination of five drugs (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) administered in cycles over several months. Radiation therapy may be used for localized disease. Immunotherapy — drugs that harness the immune system to target cancer cells — has become increasingly important. For patients whose disease relapses or does not respond to initial treatment, autologous stem-cell transplantation (using the patient’s own stem cells) may be offered. In advanced or refractory cases, CAR T-cell therapy — a complex immunotherapy in which the patient’s T-cells are genetically modified to attack cancer cells — may be an option.
The economic cost of this disease is staggering. A single course of R-CHOP can run into the tens of thousands of dollars. Stem-cell transplantation can cost hundreds of thousands. CAR T-cell therapy costs can exceed a million dollars for a single treatment course. Beyond the direct medical costs, there are lost wages during treatment — which can last months — and diminished earning capacity if the disease or its treatment leaves lasting effects. Some patients face ongoing surveillance for recurrence for years or decades, with periodic CT scans, blood tests, and specialist visits. Treatment-induced secondary malignancies are a recognized risk of some chemotherapy regimens, meaning the treatment itself can create a new cancer risk that follows the patient for life.
The non-economic cost is what no spreadsheet captures. The fear of recurrence — the “scanxiety” that builds before every follow-up imaging study. The exhaustion of chemotherapy. The hair loss, the nausea, the immune suppression that turns a common cold into a hospital stay. The missed birthdays, the canceled plans, the relationships strained by the weight of a cancer diagnosis. For patients with aggressive disease, the existential reality of facing a cancer that may not be curable. And for families who have lost a loved one to NHL, the grief, the loss of companionship, the loss of financial support, and the loss of the future they had planned together.
This is what a wrongful-death claim addresses when NHL takes a life — and what a survival action addresses when the person fought through it. The damages model in a Roundup case, post-ruling, must carefully separate the economic stream (medical costs, lost wages, diminished earning capacity, future surveillance) from the human losses (pain, suffering, fear, loss of quality of life) — and, where the evidence supports it, punitive damages grounded in allegations that the manufacturer suppressed unfavorable research and cultivated regulatory influence. A preemption ruling that narrows failure-to-warn claims may compress the punitive universe for some plaintiffs, but it does not eliminate the compensatory damages for the harm itself.
The Defendant: Bayer, Monsanto, and the Corporate Structure
Bayer AG is a German pharmaceutical and life-sciences conglomerate. In 2018, Bayer acquired Monsanto Company — the American agrochemical company that designed, tested, labeled, marketed, and distributed Roundup for decades — and assumed all Roundup-related tort liability as the successor parent entity. The acquisition cost Bayer approximately $63 billion, and the Roundup litigation that followed has been described as one of the most costly mass-tort inheritances in corporate history.
Monsanto Company, now a wholly-owned subsidiary of Bayer, was the original manufacturer of Roundup. Monsanto held the original glyphosate patent, which expired in 2000, but the company continued to formulate and sell Roundup-brand products and remained the dominant player in the glyphosate market. The internal corporate documents produced in Roundup litigation — emails, research memoranda, scientific-influence strategy documents — all bear Monsanto’s name, and the knowledge, state of mind, and potential suppression of unfavorable science that these documents may reveal are attributes of Monsanto that Bayer inherited when it acquired the company.
The corporate structure matters for several reasons. First, the entity you sue — the caption defendant — is typically Monsanto Company, not Bayer AG, because Monsanto is the entity that designed, manufactured, and labeled the product. But Bayer, as the parent, is the entity with the balance sheet, the insurance tower, and the ultimate responsibility for the liability it assumed. Understanding which entity holds the assets and which entity holds the liability is part of building a case that actually results in recovery.
Second, there may be downstream distributors and retailers in the product distribution chain — entities that sold or supplied Roundup to end-users. Secondary liability for these entities depends on jurisdiction-specific product liability doctrines and supply-chain proof. In some states, a retailer who sold a defective product may be liable even without knowledge of the defect; in others, the retailer’s liability is more limited. These entities are typically not the primary targets, but they may be part of the overall liability picture.
Third — and this matters especially for fraudulent-concealment and punitive-damages theories — the internal Monsanto documents already produced in prior discovery are the evidence that supports those claims. Emails discussing glyphosate’s carcinogenic potential, research memoranda evaluating IARC’s classification, scientific-influence strategy documents, and correspondence with EPA officials — these are the records that tell the story of what Monsanto knew, when it knew it, and what it did with that knowledge. Much of this material has already been produced in prior litigation and is subject to litigation holds. Some is partially public. Additional internal documents remain subject to protective orders. The accessibility of this evidence varies, but its existence is established.
For cases built on non-preempted theories — design defect, fraudulent concealment, consumer-protection violations — the corporate-knowledge evidence is the spine of the case. It is what separates a claim that says “this product was dangerous” from a claim that says “this company knew its product was dangerous, studied the danger internally, suppressed the unfavorable findings, and continued to market the product as safe.” The second claim is far more powerful, and it is the one that may survive a preemption ruling that narrows the first.
The Evidence Clock: What Records Exist and How Fast They Disappear
Every mass-tort case lives or dies on evidence, and evidence has a shelf life. In Roundup litigation, there are five categories of evidence, each with a different clock.
Monsanto internal corporate documents, emails, and research memoranda. These prove knowledge, state of mind, and potential suppression of unfavorable science. They support fraud and punitive theories that may survive preemption. Much of this material has already been produced in prior discovery and is subject to litigation holds — it is relatively stable. But witness availability for authentication degrades over years. Scientists who wrote internal memoranda, executives who received emails, regulatory-affairs staff who communicated with EPA — these witnesses retire, move, and pass away. The documents survive, but the people who can explain them do not, indefinitely.
EPA regulatory filings, correspondence, and registration records for glyphosate. These establish the federal regulatory baseline central to the preemption analysis and may reveal internal agency disagreements about carcinogenicity. This material is in the public record — it is permanent and there is no preservation risk. But regulatory positions can shift with future administrations, and the EPA’s current position on glyphosate may not be its position in five years.
IARC monograph and supporting scientific literature on glyphosate carcinogenicity. This provides the general-causation foundation independent of the EPA’s contrary position. It supports expert testimony on mechanism and risk. The IARC monograph is published and permanent — there is no preservation risk. The supporting peer-reviewed literature is also permanent. This is the scientific backbone for any surviving Roundup claim, and it does not degrade.
Plaintiff-specific exposure history, purchase records, and medical records. This is the evidence that establishes specific causation — the dose, the duration, and the temporal relationship between your Roundup use and your cancer diagnosis. This is where the clock is most dangerous. Retail purchase records and agricultural-use logs degrade over time. If you bought Roundup at a hardware store ten years ago, that receipt is probably gone. If you used Roundup professionally — as a farmer, a landscaper, a groundskeeper, a parks employee — your employer’s records may still exist, but they may also have been purged. Medical records are more durable but should be obtained immediately for any new filing. The sooner these records are gathered, the stronger the specific-causation proof.
Monsanto scientific-influence and ghostwriting documentation. This supports fraudulent-concealment and punitive theories that may survive a preemption ruling focused on labeling claims. Much of this was produced in prior litigation and is partially public. Additional internal documents remain subject to protective orders. The preservation risk is low for already-produced material, but access to protective-order material requires participation in the litigation or coordination with firms that already have access.
The practical lesson is this: the fastest-dying evidence is yours. The Monsanto documents are largely locked down. The EPA filings are permanent. The IARC monograph is permanent. But your purchase records, your employment records, your exposure history — those are the records that erode, and they are the records that prove your specific case. Gathering them is the first thing that happens when a toxic-tort case opens, and the preservation demand goes out before anything else.
What Your Case May Be Worth After the Ruling
We are going to be honest with you about case value, because honesty is the only thing that serves you here. The ruling changes the value landscape, and pretending it does not would be a disservice.
Before the ruling, the Roundup litigation had produced individual verdicts in the tens of millions of dollars in bellwether cases, and Bayer’s global settlement framework allocated billions of dollars across tens of thousands of claims. Failure-to-warn was the primary theory, and it was the theory that drove both the verdicts and the settlement values. Cases with strong specific-causation proof — long-term, heavy exposure to Roundup followed by an NHL diagnosis with few alternative risk factors — commanded the highest values, particularly in favorable venues.
After the ruling, the value landscape compresses on one end and potentially sharpens on the other.
For cases built primarily on failure-to-warn theory, the ruling likely compresses value toward zero if that theory is fully preempted and no alternative theory is viable. A case that said only “the label should have warned about cancer” and cannot be reframed as a design-defect, fraudulent-concealment, or consumer-protection claim may have little or no remaining value. That is the hard truth.
For cases built on surviving theories — design defect with strong causation proof, fraudulent concealment with internal-document evidence of suppression, consumer-protection violations with deceptive-marketing evidence — the value range remains in the multi-million-dollar territory for severe NHL with strong specific-causation proof in a favorable venue. The economic damages alone (medical treatment, lost wages, diminished earning capacity) can run from the hundreds of thousands to over a million dollars for a single patient. Non-economic damages (pain, suffering, loss of quality of life) add substantially on top. And punitive damages, where the evidence of suppression and deception supports them, can multiply the total.
The forensic economics of a post-ruling landscape require careful separation of preempted from non-preempted theories before projecting any recovery. A life-care planner builds the cost stream — every surgery, every treatment cycle, every medication, every surveillance scan, every year of lost earning capacity — and a forensic economist reduces it to present value. That number is the floor. The human losses are built on top of it. And the punitive exposure, where it survives, is built on top of that.
Past results depend on the facts of each case and do not guarantee future outcomes. What your specific case is worth depends on the opinion’s exact scope, the surviving liability theories, your jurisdiction’s tort-reform environment (damage caps, comparative-fault rules, punitive-damages limitations), and the strength of your specific causation proof. No lawyer can give you a number without reviewing your case. Any lawyer who gives you a number without reviewing your case is not telling you the truth.
The Defense Playbook: What Bayer’s Lawyers Will Do Next
Bayer’s legal team is not going to wait for plaintiffs to regroup. They have a winning ruling from the Supreme Court, and they are going to use it. Here are the plays we expect to see — and here is how each one is countered.
Play 1: “Your entire claim is preempted.” Bayer will file motions to dismiss or for summary judgment arguing that the Supreme Court’s ruling forecloses not just failure-to-warn claims but every related state-law claim. They will push the opinion’s language as far as it can go, arguing for the broadest possible preemption scope.
The counter: the opinion’s language is the opinion’s language — not Bayer’s preferred interpretation of it. If the Court’s holding is limited to labeling requirements, then claims based on design defect, fraudulent concealment, and consumer-protection violations that do not depend on labeling are not preempted. The response brief must carefully parse the opinion’s exact scope and demonstrate that the surviving claims fall outside its reach. Overreading a preemption holding is a defense move, not a defense fact.
Play 2: “Settle for pennies or walk away.” Bayer may harden its settlement posture, offering fractions of pre-ruling values for claims it believes are preempted, or refusing to engage at all on those claims. The message will be: “take what we are offering, because your case is not worth litigating anymore.”
The counter: a claim built on a non-preempted theory — with strong causation proof, internal-document evidence of suppression, and a favorable forum — is not a claim that should be settled for pennies. The asymmetric leverage cuts both ways. Bayer knows that preempted claims are dropping out of the inventory, which means the remaining claims are the ones with teeth. A well-pleaded surviving claim may actually have more settlement value, not less, because Bayer knows it can actually reach a jury.
Play 3: “Your cancer came from something else.” The causation defense will intensify. NHL has multiple known risk factors — age, immune suppression, certain infections, family history, other chemical exposures. Bayer’s experts will argue that your NHL was idiopathic (of unknown cause) or attributable to a factor other than Roundup.
The counter: dose-response modeling against documented exposure history, temporal relationship between Roundup use and diagnosis, confounder screening that rules out alternative causes, and the IARC classification as the general-causation foundation. Specific causation is harder than failure-to-warn, but it is provable with the right experts and the right exposure record. The defense’s argument that NHL is “usually idiopathic” is an argument, not a fact — and it is an argument that a qualified oncologist or epidemiologist can rebut with case-specific evidence.
Play 4: “The EPA said it was safe.” Bayer will lean on the EPA’s historical position that glyphosate is “not likely to be carcinogenic to humans” as evidence that the product was not dangerous and that any failure to warn was the result of reasonable reliance on a federal agency’s determination.
The counter: the EPA’s position has been contested, has been criticized by IARC, and has been the subject of internal agency disagreement. The scientific dispute between the EPA and IARC is exactly that — a scientific dispute, not a settled fact. A jury is entitled to hear both positions and to weigh the evidence. The EPA’s regulatory determination is relevant to the preemption question, but it is not conclusive on the question of whether the product actually caused your cancer.
How a Surviving Roundup Case Is Built
Here is the chronological walk of how a surviving Roundup case — one built on a non-preempted theory — is actually constructed, from the day you call to the day a number is on the table.
Week one: the intake and the opinion analysis. The first thing that happens is a case-specific evaluation. Which theory was your case filed under, or which theory could it be filed under? Does that theory survive the opinion’s scope? What is the deadline in your state, and has it run? The lawyer reads the opinion — not the headline, not the press summary, the actual opinion — and maps its holding against your specific claims. If the case survives this analysis, the next steps follow. If it does not, the honest answer is that it does not, and you deserve to hear that from a lawyer who has actually done the analysis rather than guessing from a news article.
Weeks two through four: evidence gathering and preservation. Exposure history is documented — when, where, how often, and for how long you used Roundup. Purchase records are sought from retailers, if they still exist. Employment records are obtained if exposure was occupational. Medical records are pulled — the complete set, from diagnosis through treatment, including pathology reports confirming the NHL subtype, treatment records documenting the regimen, and follow-up records showing the disease course. A preservation letter goes out to any employer, retailer, or other entity that may hold exposure-related records, ordering them not to destroy those records.
Months one through three: expert selection and case development. General-causation experts are retained — typically an oncologist, epidemiologist, or toxicologist who can testify that glyphosate is capable of causing NHL, supported by the IARC classification and the peer-reviewed literature. Specific-causation experts are retained — typically a physician or epidemiologist who can perform dose-response modeling, evaluate the temporal relationship between your exposure and your diagnosis, screen for confounders (other known NHL risk factors), and render an opinion that your Roundup exposure was a substantial factor in causing your cancer. If the case includes a fraudulent-concealment theory, the corporate-document evidence — internal Monsanto emails, research memoranda, scientific-influence strategy documents — is assembled and analyzed.
Months three through six: discovery and depositions. If the case is in litigation, discovery proceeds. Written interrogatories, document demands, and depositions of Monsanto’s corporate representatives follow. The depositions are where the corporate-knowledge evidence comes alive — where a Monsanto scientist or executive is asked, under oath, about what the company knew regarding glyphosate’s carcinogenic potential, when it knew it, and what it did with that knowledge. The design-defect theory is developed through discovery into the product’s formulation, testing history, and the existence of safer alternatives. The fraudulent-concealment theory is developed through discovery into internal communications, scientific-influence operations, and the relationship between Monsanto’s public statements and its private knowledge.
Months six through twelve: the number. The economic damages are built by a life-care planner and reduced to present value by a forensic economist. The non-economic damages are framed by the human story — what the disease took from this person, what the treatment cost in pain and lost years, what the future looks like with a cancer that may recur. The punitive exposure, where the evidence supports it, is calculated based on the defendant’s financial condition and the degree of reprehensibility of the conduct. The demand is built from all of it, and the negotiation begins.
This is not a fast process. It is a thorough one. And the thoroughness is what separates a case that settles for a fraction of its value from one that settles — or is tried — for what it is actually worth.
Your First 72 Hours: What to Do Now
If you used Roundup and have been diagnosed with non-Hodgkin lymphoma, or if you lost a family member to NHL and they had a history of Roundup exposure, and you are reading about this ruling and wondering what to do — here is the practical roadmap.
Do not panic. The ruling is significant, but it is not the end of every claim. Read the section above on which theories may survive. If your case could be built on a non-preempted theory, the door may still be open.
Do not sign anything. If you receive a communication from Bayer, from a claims administrator, from a settlement facility, or from any entity offering to resolve your potential claim — do not sign it, do not cash a check, and do not accept anything without speaking to a lawyer first. A release signed in haste can extinguish rights you do not yet know you have.
Do not give a recorded statement. If an insurance adjuster, a claims representative, or anyone purporting to act on behalf of Bayer or Monsanto contacts you and asks you to describe your exposure history or your medical condition on a recorded line, decline. Recorded statements are engineered to lock you into a narrative that serves the person recording, not you.
Gather your exposure history. Write down everything you can remember about your Roundup use: what product you used (Roundup brand, concentration, formulation), where you bought it, how often you used it (daily, weekly, seasonally), how many years you used it, whether you used it professionally or personally, what kind of application method you used (spray bottle, pump sprayer, backpack sprayer, tractor-mounted sprayer), and whether you used protective equipment. This information degrades in memory — write it down now, while it is fresh.
Gather your medical records. Obtain copies of your complete medical records related to your NHL diagnosis and treatment: pathology reports, chemotherapy records, imaging studies, hospital discharge summaries, specialist notes, and follow-up records. These are more durable than exposure records but should be obtained promptly.
Do not post about your case on social media. Anything you post — about your health, about Roundup, about the ruling, about lawyers — can be found and used by the other side. This is not paranoia; it is standard defense practice.
Call a lawyer. Not just any lawyer — a lawyer who handles toxic-tort cases, who has read the opinion, who can evaluate whether your specific case has a surviving theory, and who can tell you honestly whether the door is open or closed. The consultation should be free. The fee should be contingent — meaning the lawyer only gets paid if you recover. And the lawyer should be able to explain, in language you understand, what your options are and what the timeline looks like.
You can reach us at 1-888-ATTY-911. The call is free. We answer 24 hours a day — not an answering service, live staff. And if we are not the right fit for your case, we will tell you that, too.
Why Attorney911
Ralph Manginello is our Managing Partner. He has been licensed to practice law in Texas since November 6, 1998 — 27 years in courtrooms, including federal court. He was a journalist before he was a lawyer, which means he reads closely, writes precisely, and does not accept the first version of a story he is told. He is admitted to the U.S. District Court for the Southern District of Texas. He is a member of the Texas Trial Lawyers Association and the Houston Bar Association. He leads the active $10 million hazing lawsuit against Pi Kappa Phi and the University of Houston in Harris County. When a Supreme Court ruling drops that could change the landscape for thousands of people with cancer, he reads the opinion — not the headline.
Lupe Peña is our Associate Attorney. He was licensed in Texas in 2012. Before he joined this firm, he spent years inside a national insurance-defense firm — the rooms where adjusters and their software decide how to deny, delay, and devalue claims exactly like yours. He knows how the other side values a claim, how it picks its IME doctors, how it runs surveillance, and how it uses delay tactics to push plaintiffs past their deadlines. Now he uses that knowledge for injured clients. He is fluent in Spanish and conducts full client consultations in Spanish without an interpreter.
We work on contingency. That means our fee is 33.33 percent before trial and 40 percent if the case goes to trial. We do not get paid unless we win your case. The first consultation is free. And the answer you get from us about your case — whether it is “we can help” or “this claim is not viable after the ruling” — will be the honest one, because the truth is what serves you, and it is what we would want for our own families.
We serve clients in English and in Spanish. Hablamos Español.
Frequently Asked Questions
Is my Roundup case over because of the Supreme Court ruling?
It depends on what theory your case was filed under. If your case is built primarily on failure-to-warn — the claim that Monsanto should have put a cancer warning on the Roundup label — the ruling may foreclose that theory. But if your case includes or could be reframed as a design-defect claim, a fraudulent-concealment claim, or a state consumer-protection claim, those theories may survive. The only way to know is a case-specific evaluation by a lawyer who has read the opinion and can map its holding against your specific claims. Do not assume your case is dead based on a headline.
Can I still file a new Roundup lawsuit after the ruling?
Potentially, yes — but the path is narrower. A new case filed on a failure-to-warn theory may face an immediate preemption motion. A new case filed on a design-defect theory, with strong specific-causation proof and in a favorable forum, may still proceed. The decision of whether, where, and how to file has become more strategic. You also need to check the statute of limitations in your state — many states apply a discovery rule for latent diseases, meaning the clock may start around the date of diagnosis, but some states have statutes of repose that can cut off claims earlier. This is not something to guess about; it requires a lawyer to check.
What is FIFRA preemption and why does it matter for my case?
FIFRA is the federal law that governs pesticide labeling. It requires the EPA to approve pesticide labels before sale. FIFRA also contains an express preemption provision that bars states from imposing labeling requirements different from or in addition to what the federal scheme requires. The Supreme Court’s ruling means that the EPA’s approval of Roundup’s label (without a cancer warning) may preempt state-law claims that would require a cancer warning — because imposing that warning through a state tort judgment would be a labeling requirement “different from” what the EPA approved. This matters because failure-to-warn has been the primary theory in Roundup litigation, and if that theory is preempted, cases built solely on it may not proceed.
What legal theories might survive the ruling?
Several theories may survive, depending on the opinion’s exact scope. Design defect — the claim that the product’s chemical formulation was unreasonably dangerous as designed, independent of the label — may survive because it does not depend on labeling requirements. Fraudulent concealment — the claim that Monsanto suppressed unfavorable research and deceived the public — may survive if grounded in an independent duty not to deceive rather than a duty to warn through the label. State consumer-protection statutes — claims based on deceptive marketing and unfair trade practices — may provide an alternative avenue not directly addressed by a FIFRA preemption holding. Negligence in testing and research — the claim that Monsanto failed to exercise reasonable care in studying glyphosate’s long-term effects — may survive as a non-labeling theory. The common thread: the further the claim gets from “the label should have said something different,” the more likely it survives.
What happens to my case if it was already filed in the MDL?
If your case is in the Roundup MDL (MDL-2741, Northern District of California, Judge Chhabria), the ruling changes the landscape for your pending case. Monsanto may file motions to dismiss or for summary judgment arguing that your failure-to-warn claims are preempted. The MDL court will need to determine how the opinion applies to the pending inventory. Cases that include non-preempted theories may proceed; cases built solely on preempted theories may face dismissal. Your lawyer should be evaluating your case’s specific theories against the opinion’s scope and, if necessary, amending the complaint to add or emphasize non-preempted claims. If you are not sure whether your lawyer has done this, ask them — directly.
How long do I have to file a Roundup claim?
The deadline depends on your state. Personal-injury statutes of limitations typically range from two to six years, depending on the jurisdiction. For latent diseases like NHL, many states apply a discovery rule — the clock starts when you knew or should have known of the injury and its connection to the exposure, not when you were exposed. This often means the clock starts around the date of diagnosis. But some states also have statutes of repose — outer deadlines that can cut off claims even before discovery. The discovery rule does not defeat a statute of repose. You need a lawyer in your state to check the specific deadline. Do not wait, because the clock may already be running.
What is non-Hodgkin lymphoma and how is it connected to Roundup?
Non-Hodgkin lymphoma is a cancer of the lymphatic system, which is part of the immune system. It begins when white blood cells called lymphocytes develop abnormalities and multiply uncontrollably. There are more than 70 subtypes, with survival rates varying dramatically by type and stage. Treatment may include R-CHOP chemotherapy, radiation, immunotherapy, and in advanced cases, stem-cell transplantation or CAR T-cell therapy. The connection to Roundup is through glyphosate, the active ingredient. In 2015, the International Agency for Research on Cancer classified glyphosate as “probably carcinogenic to humans.” The EPA has historically maintained that glyphosate is “not likely to be carcinogenic.” This scientific dispute is the foundation of the litigation — and it is why general-causation expert testimony (that glyphosate can cause NHL) and specific-causation expert testimony (that your Roundup exposure caused your NHL) are central to any surviving case.
What should I do right now if I used Roundup and have been diagnosed with NHL?
First, do not sign anything from Bayer, Monsanto, any claims administrator, or any insurance representative. Second, write down your complete Roundup exposure history — what product, how often, how many years, professional or personal use. Third, obtain your complete medical records related to your NHL diagnosis and treatment. Fourth, do not post about your case on social media. Fifth, call a lawyer who handles toxic-tort cases and who has read the Supreme Court’s opinion. The consultation should be free. Ask the lawyer directly: “Does my case have a theory that survives the ruling?” If the answer is yes, ask what the next steps are and what the timeline looks like. If the answer is no, get a second opinion — but get it quickly, because the clock may be running.
Will Bayer still settle Roundup cases after the ruling?
Bayer’s settlement posture will likely split. For claims it believes are fully preempted — primarily failure-to-warn claims with no viable alternative theory — Bayer may offer less or refuse to settle, betting that courts will dismiss those claims. For claims built on non-preempted theories — design defect, fraudulent concealment, consumer-protection violations — Bayer remains exposed and may continue to settle, because those claims can reach a jury and because the internal-document evidence of suppression and deception is already public. The asymmetric leverage works both ways: preempted claims lose value, but surviving claims may retain or increase their settlement value because they are the ones with teeth. Whether Bayer will settle your specific claim depends on your theory, your evidence, and your forum.
Does the ruling affect state-court cases differently than federal-court cases?
The Supreme Court’s preemption ruling is the supreme law of the land under the Supremacy Clause — it binds every federal and state court in the country. No state court can ignore it. However, state courts may interpret the opinion’s scope differently, and state-specific legal frameworks — consumer-protection statutes, unfair-trade-practices acts, comparative-fault rules, damage caps, and statutes of limitations — may create pathways that are not directly addressed by the federal preemption holding. Forum selection has always mattered in mass-tort litigation; after this ruling, it matters more. A case filed in a state with strong consumer-protection laws and a plaintiff-friendly tort climate may have more surviving options than the same case filed in a state with tort-reform caps and no consumer-protection alternative. Your lawyer should be evaluating forum strategically, not just filing wherever is convenient.
How do I know if my lawyer is handling this ruling correctly?
Ask your lawyer three direct questions. First: “Have you read the actual Supreme Court opinion, and what is its exact scope?” If the lawyer cannot answer this in specific terms, that is a concern. Second: “Does my case include any theories that are not failure-to-warn — such as design defect, fraudulent concealment, or state consumer-protection claims?” If the answer is no, ask why not, and whether amendment is possible. Third: “What is the statute of limitations in my state, and has it run?” If the lawyer cannot answer this precisely, get a second opinion. These are not aggressive questions. They are the questions a competent lawyer should welcome, because they show you are paying attention.
What if I already settled my Roundup claim — does the ruling change anything?
Generally, no. A settled claim — one where you signed a release and accepted payment — is final, regardless of the ruling. The ruling may affect the value of future settlements and the leverage of unresolved claims, but it does not reopen completed ones. The exception would be if there was fraud in the settlement process itself — for example, if material information was concealed from you at the time of settlement. That is a narrow and fact-specific exception, and it is not created by the Supreme Court’s preemption ruling. If you have concerns about a settlement you already signed, a lawyer can review the release and the circumstances — but do not assume the ruling gives you grounds to reopen it.
If you are reading this at 2 a.m. because you just saw the headline and your stomach dropped — we understand. You have questions that a news article cannot answer. You have fears that a legal doctrine you have never heard of has just been used to shield the company whose product may have changed your life. And you have a right to honest, specific, case-focused answers from a lawyer who has read the opinion, not the press release.
Call us at 1-888-ATTY-911. The consultation is free. We do not get paid unless we win your case. And the first thing we will do is the same thing we would want done for our own family: read the opinion, check your deadline, and tell you the truth about whether your case has a path forward.
This page is legal information, not legal advice. Past results depend on the facts of each case and do not guarantee future outcomes. Contacting the firm is free and confidential.